MarketsandMarkets forecasts the NLP in healthcare & life sciences market to expand nearly fourfold to $30.1 billion by 2031, signaling rapid AI adoption in medical settings
Executive summary: MarketsandMarkets published a market forecast estimating the NLP in healthcare & life sciences market will rise from $8.14 billion in 2026 to $30.06 billion by 2031, a CAGR of 29.9%. The forecast highlights a rapid acceleration of AI‑driven language tools in clinical and research settings, which could reshape healthcare delivery costs, improve diagnostic speed, and create sizable revenue opportunities for vendors.
Who is involved: MarketsandMarkets (research firm), healthcare providers, pharmaceutical companies, and NLP/AI technology vendors such as IBM Watson Health, Google Health, and Nuance Communications.
Likely next: Expect increased vendor product launches, potential FDA draft guidance on AI/ML‑based SaMD for NLP applications later in 2026, and heightened M&A activity as larger health IT firms seek to acquire niche NLP startups.
According to a MarketsandMarkets report released July 15, 2026, the natural language processing (NLP) segment within healthcare and life sciences is projected to grow from USD 8.14 billion in 2026 to USD 30.06 billion by 2031, reflecting a compound annual growth rate of 29.9%. The expansion is driven by increasing use of NLP for clinical documentation, patient engagement, and drug discovery workflows. Analysts note that the growth trajectory assumes continued investment in AI‑enabled health IT and favorable regulatory treatment of AI‑based software as a medical device.
Timeline
- — NLP in Healthcare & Life Sciences Market worth $30.06 billion by 2031 - Report by MarketsandMarkets™ (PR Newswire)
Analysis — what this means
Likely next events
- MarketsandMarkets to issue an updated NLP healthcare forecast in Q4 2026.
- FDA anticipated to release draft guidance on AI/ML‑based SaMD for NLP applications by September 30 2026.
- HLTH 2026 healthcare AI conference scheduled for October 12‑15 2026 in Las Vegas, featuring NLP use‑case sessions.
- Patient‑specific implant market projected to cross the $6 billion threshold in 2027 according to Future Market Insights.
Sectors affected
- Natural language processing in healthcare
- Clinical documentation automation
- Patient‑specific surgical implant manufacturing
- Longevity and preventive health services
Regulatory implications
- FDA’s Software as a Medical Device (SaMD) framework may apply to NLP tools used for diagnosis, requiring 510(k) clearance.
- EU AI Act classifies high‑risk AI in medical devices, imposing conformity assessment by August 2027.
- HIPAA updates expected in 2027 to address privacy and security of AI‑generated patient data.
Historical parallels
- HITECH Act (2009) spurred EHR adoption from ~20% to >80% of US hospitals by 2015.
- IBM Watson Health launch in 2015 promised AI‑driven oncology insights but faced commercial challenges by 2022.
- First FDA‑cleared AI radiology tool (IDx‑DR) received clearance in 2018, setting a precedent for AI‑based SaMD.
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped